Login to Your Account



VelocImmune Scores Big Again

Regeneron Banking $165M on Expanded Astellas Agreement

By Jennifer Boggs


Thursday, July 29, 2010
Regeneron Pharmaceuticals Inc. expanded its nonexclusive deal with Astellas Pharma Inc. through 2023 in exchange for $165 million up front, bringing total committed funding stemming from licenses to its VelocImmune mouse antibody platform to roughly $2 billion. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription